Medipharm Labs Corp
TSX:LABS

Watchlist Manager
Medipharm Labs Corp Logo
Medipharm Labs Corp
TSX:LABS
Watchlist
Price: 0.065 CAD Market Closed
Market Cap: 27.3m CAD

Medipharm Labs Corp
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Medipharm Labs Corp
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Medipharm Labs Corp
TSX:LABS
EPS (Diluted)
CA$0
CAGR 3-Years
50%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
EPS (Diluted)
$0
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
-5%
Canopy Growth Corp
TSX:WEED
EPS (Diluted)
-CA$1
CAGR 3-Years
40%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Sundial Growers Inc
NASDAQ:SNDL
EPS (Diluted)
CA$0
CAGR 3-Years
32%
CAGR 5-Years
53%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
EPS (Diluted)
$0
CAGR 3-Years
N/A
CAGR 5-Years
-20%
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
EPS (Diluted)
CA$0
CAGR 3-Years
41%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Medipharm Labs Corp
Glance View

Market Cap
27.3m CAD
Industry
Pharmaceuticals

MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 190 full-time employees. The company went IPO on 2018-02-09. The firm produces purified, pharmaceutical-like cannabis extracts and related derivative products. The firm formulates, processes, packages and distributes cannabis extracts and cannabinoid-based products at its Canadian and Australian facilities for domestic and international markets. The Company, through its subsidiaries is engaged in the sale and distribution of cannabis oil, cannabis extracts, cannabis edibles, cannabis topicals, and derivatives to authorized classes of purchasers, as well as controlled human administration trials for sensory testing of cannabis extracts and derivative products. The company is also engaged in the manufacturing of extracts and tinctures of cannabis and cannabis resin for the purpose of a clinical trial or prescribed as medical cannabis products. The firm's wholly owned subsidiaries include MediPharm Labs Inc. and MediPharm Labs Australia Pty. Ltd.

LABS Intrinsic Value
HIDDEN
Show

See Also

What is Medipharm Labs Corp's EPS (Diluted)?
EPS (Diluted)
-0 CAD

Based on the financial report for Sep 30, 2025, Medipharm Labs Corp's EPS (Diluted) amounts to -0 CAD.

What is Medipharm Labs Corp's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
41%

Over the last year, the EPS (Diluted) growth was 33%. The average annual EPS (Diluted) growth rates for Medipharm Labs Corp have been 50% over the past three years , 41% over the past five years .

Back to Top